Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 

Slides:



Advertisements
Similar presentations
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Advertisements

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: A comparison of three-year survival after coronary.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Peter K. Smith, MD, Robert M. Califf, MD, Robert H
Figure 1 A flow chart describing the systematic process followed for article selection.  From: A systematic review of cost-effectiveness of percutaneous.
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease  Ralf.
Glenn N. Levine et al. JACC 2016;68:
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
Technological innovation in cardiothoracic surgery: A pragmatist's approach  Pedro J. del Nido, MD  The Journal of Thoracic and Cardiovascular Surgery 
Glenn N. Levine et al. JACC 2016;68:
Cyrus J. Parsa, MD, Linda K. Shaw, MS, J. Scott Rankin, MD, Mani A
The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting  Danny Chu, MD, Faisal.
Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease  Ralf.
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis  Peter Donndorf, MD, Guenther Kundt, PhD,
The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy  John W.C.
Standardizing definitions for hybrid coronary revascularization
The present day potential role of fractional flow reserve–guided coronary artery bypass graft surgery  Filip Casselman, MD, PhD, FETCS, Johan Van der.
Manesh R. Patel, MD, FACC, Gregory J
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Short- and intermediate-term outcomes of hybrid coronary revascularization for double- vessel disease  Nirav C. Patel, MD, Jonathan M. Hemli, MD, Michael.
Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies  Hisato Takagi,
P. Foëx  British Journal of Anaesthesia 
CD133+ cells: How could they have an IMPACT?
The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention.
Peter K. Smith, MD  The Annals of Thoracic Surgery 
J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K
Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy  Eric J. Velazquez, MD,
Juan A. Crestanello, MD, Richard C. Daly, MD 
Coronary artery bypass grafting is superior to first-generation drug-eluting stents for unprotected left main coronary artery disease: An updated meta-analysis.
Defining operative mortality: Impact on outcome reporting
Why surgery won the SYNTAX trial and why it matters
Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS 
Michael E. Halkos, MD, MSc, Henry A
Appropriateness of Coronary Revascularization for Patients Without Acute Coronary Syndromes Edward L. Hannan, PhD; Kimberly Cozzens, MA; Zaza Samadashvili,
Multilevel data analysis: What? Why? How?
Harold L. Lazar, MD  The Journal of Thoracic and Cardiovascular Surgery 
Risk Stratification and Interventional Cardiology: Robert L
Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris  Toshihiro Fukui,
Minimally invasive direct coronary artery bypass improves late survival compared with drug-eluting stents in isolated proximal left anterior descending.
Surgical economics: MACRA, MIPS, and bundles—Lessons learned in the first 3 years of a coronary artery bypass grafting alternative payment model  Daniel.
Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD 
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Long Segmental Reconstruction of Diffusely Diseased Left Anterior Descending Coronary Artery With Left Internal Thoracic Artery With or Without Endarterectomy 
For everything there is a season
Survival probability loss from percutaneous coronary intervention compared with coronary artery bypass grafting across age groups  Umberto Benedetto,
Peter K. Smith, MD, Robert M. Califf, MD, Robert H
To bypass or stent? The changing rules of an advancing game
Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.
Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass  Benjamin Medalion, MD, Michael G. Katz, MD,
Current Clinical Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting  Michael J. Mack, MD, Syma L. Prince, RN, Morley Herbert,
Glenn N. Levine et al. JACC 2011;58:e44-e122
Survival After Isolated Coronary Artery Bypass Grafting in Patients With Severe Left Ventricular Dysfunction  Waleed A. Ahmed, MD, Phillip J. Tully, BHSc(Hons),
Discussion The Journal of Thoracic and Cardiovascular Surgery
Comparison of 30-day outcomes of coronary artery bypass grafting surgery verus hybrid coronary revascularization stratified by SYNTAX and euroSCORE  Marzia.
Davide Capodanno et al. JCIN 2009;2:
Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization  Paul Kurlansky, MD, Morley Herbert, PhD, Syma.
Transatlantic editorial: A comparison between European and North American guidelines on myocardial revascularization  Philippe Kolh, MD, PhD, Paul Kurlansky,
Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know  Harold L. Lazar,
The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization  Lorenzo Azzalini,
American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons  Richard J.
Utilization and Outcomes of Unprotected Left Main Coronary Artery Stenting and Coronary Artery Bypass Graft Surgery  Chuntao Wu, MD, PhD, Edward L. Hannan,
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Treatment selection for coronary artery disease: The collision of a belief system with evidence  Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 137, Issue 5, Pages 1050-1053 (May 2009) DOI: 10.1016/j.jtcvs.2009.03.043 Copyright © 2009 The American Association for Thoracic Surgery and The Society of Thoracic Surgeons Terms and Conditions

Figure 1 Adjusted long-term actuarial survival for 18,481 Duke University patients (1986 to 2003) with severe coronary artery disease treated with medical therapy (black line) compared with revascularization by percutaneous coronary intervention or coronary artery bypass grafting (red line). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 1050-1053DOI: (10.1016/j.jtcvs.2009.03.043) Copyright © 2009 The American Association for Thoracic Surgery and The Society of Thoracic Surgeons Terms and Conditions

Figure 2 Appropriateness criteria result for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with coronary artery disease extent considered sufficient for appropriateness of revascularization, stratified by extent of disease and association of diabetes or impaired left ventricular function. A, Appropriate; U, uncertain; I, inappropriate; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction. This figure is reproduced, with permission, from “Appropriateness Criteria for Coronary Revascularization” by Patel MR, et al. J Am Coll Cardiol. 2009;53:545. Copyright 2009 American College of Cardiology Foundation. The Journal of Thoracic and Cardiovascular Surgery 2009 137, 1050-1053DOI: (10.1016/j.jtcvs.2009.03.043) Copyright © 2009 The American Association for Thoracic Surgery and The Society of Thoracic Surgeons Terms and Conditions

Figure 3 Changing patterns of initial treatment selection among medical therapy (MED, yellow line), percutaneous coronary intervention (PCI, red line), and coronary artery bypass grafting (CABG, blue line) from 2000 to 2008 at Duke University in 10,149 patients. Decline in CABG selection is seen after drug-eluting stent (DES) introduction, with a corresponding increase in PCI. The presentation of DES acute thrombosis as a concern resulted in a decline in PCI but an increase in medical therapy selection rather than CABG. Reconciliation occurred through observational analysis and expert opinion that indefinite dual antiplatelet therapy and decreasing DES use may limit acute stent thrombosis. With the presentation of the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial, PCI recommendations have returned to 2004 levels. The Journal of Thoracic and Cardiovascular Surgery 2009 137, 1050-1053DOI: (10.1016/j.jtcvs.2009.03.043) Copyright © 2009 The American Association for Thoracic Surgery and The Society of Thoracic Surgeons Terms and Conditions